EZH2 and uterine cervix carcinoma in situ: Meanwhile, we compared CIN III and CC groups and found significant differences in HSP90AA1, ICAM1, EZH2, ARG2, and macrophage M1, indicating these may be biomarkers for predicting CIN III’s progression to CC.